Cushing's Disease Clinical Trial
— MEMOCUSHOfficial title:
Cognitive Sequels of Cushing Syndrome
Cushing's disease is a state of chronic endogenous glucocorticoid excess. Cushing's disease is responsible for increased morbidity and mortality. Recent studies have pinpointed the frequency of somatic sequelas and persistent alteration in quality of life despite the cure of the disease. More specifically, a few studies have described persistent psychopathology, maladaptive personality and cognitive impairments in patients with a history of Cushing's disease. Among these, hippocampal memory deficits have been found in the majority of studies, a finding that is consistent with the alterations described in hippocampal neurons during chronic exposure to glucocorticoids. However, the tools currently available to assess hippocampal-dependent memory are multiple, sometimes difficult to perform by clinicians and to analyze or may lack of diagnostic sensitivity. The investigators have recently developed an original tool, the virtual radial task in 3D, which has shown to be reliable to detect subtle alterations in hippocampal-dependent memory in several human diseases. The primary aim of the study is the evaluation of persistent cognitive impairments (hippocampal memory) in patients cured of Cushing's disease for at least one year using the virtual radial task in 3D and to compare it with that obtained with classical cognitive tests.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | May 2017 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: Patients : - history of Cushing's Disease - aged : 18 - 60 years - Biological remission of Cushing's disease for at least one year - Affiliation to Social Security - Informed consent signed by patient and investigator (at the latest the inclusion's day, before study's exams) For controls : - People aged 18 to 60 years matched to patients for age, sex and educational level - Affiliation to Social Security - Informed consent signed by patient and investigator (at the latest the inclusion's day, before study's exams) Exclusion Criteria: For patients : - Persistent hypercortisolism (even mild) - Current treatment of hypercortisolism with drugs - Obesity (BMI >30 kg/m²) - Alcohol or drug addiction present or past - Growth hormone deficit - Diabetes mellitus with hemoglobin A1c > 7.5% and/or fasting blood glucose > 1.4 g/L - History of pituitary radiotherapy - History of cerebrovascular or neuro-cerebral disease - untreated dysthyroidism - Current psychotropic drug treatment - Pregnancy - Use of glucocorticoids in the last 3 months before study (aside hydrocortisone replacement therapy) - Excessive hydrocortisone replacement therapy (unadjusted to weight and/or with evening administration) For controls : - Obesity (BMI >30 kg/m²) - Alcohol or drug addiction present or past - Current psychotropic drug treatment - History of cerebrovascular or neuro-cerebral disease - Current pregnancy - Chronical use of corticoid (> 1 month), current or past - Use of glucocorticoids in the last 3 months before study (aside hydrocortisone replacement therapy) - Diabetes mellitus with hemoglobin A1c > 7.5% and/or fasting blood glucose > 1.4 g/L - Obesity (BMI >30 kg/m²) - untreated dysthyroidism |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
France | Hôpital du Haut-Lévêque | Pessac |
Lead Sponsor | Collaborator |
---|---|
Institut National de la Santé Et de la Recherche Médicale, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of right answers at virtual radial task in 3D | Comparison of right answers in patients cured of Cushing's disease and in controls. | baseline | Yes |
Secondary | General Quality of life | Comparison of quality of life of patients and controls with validated general questionnaire : SF-36 (SF for Short Form health survey) | baseline | Yes |
Secondary | Specific Quality of life for Cushing's Disease | Comparison of quality of life of patients and controls with validated specific questionnaire for Cushing's Disease : Cushing-QoL | baseline | Yes |
Secondary | Number of participants with anxiety | Evaluation of anxiety in the two groups with Hospital Anxiety and Depression Scale (HADS) scale (questionnaire) | baseline | Yes |
Secondary | Number of participants with depression with MADRS | Evaluation of depression in the two groups with Montgomery and Asberg Depression Rating Scale (MADRS) (questionnaire) | baseline | Yes |
Secondary | Number of participants with depression with HADS | Evaluation of depression in the two groups with Hospital Anxiety and Depression Scale (HADS) scale (questionnaire) | baseline | Yes |
Secondary | Intensity of Cushing's syndrome | Intensity of Cushing's disease will be evaluated with mean of free urinary cortisol. Hypothesis : intensity of hypercortisolism is correlated with sequels after cure. | baseline | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00881283 -
Long-term Cardiovascular Risk in Cured Cushing's Patients
|
||
Completed |
NCT02568982 -
Cushing's Disease Complications
|
||
Completed |
NCT02697734 -
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
|
Phase 3 | |
Completed |
NCT01374906 -
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
|
Phase 3 | |
Recruiting |
NCT03364803 -
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
|
||
Completed |
NCT01371565 -
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
|
Phase 3 | |
Recruiting |
NCT00845351 -
Preoperative Bexarotene Treatment for Cushing's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00889525 -
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
|
Phase 3 | |
Completed |
NCT02060383 -
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
|
Phase 4 | |
Recruiting |
NCT03474601 -
Seoul National University Pituitary Disease Cohort Study
|
||
Recruiting |
NCT04339751 -
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease
|
Phase 2 | |
Not yet recruiting |
NCT04569591 -
Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease
|
N/A | |
Recruiting |
NCT02484755 -
Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease
|
Phase 2 | |
Completed |
NCT01794793 -
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
|
Phase 4 | |
Completed |
NCT00434148 -
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
|
Phase 3 | |
Completed |
NCT03346954 -
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease
|
N/A | |
Withdrawn |
NCT01925092 -
Mifepristone in Children With Refractory Cushing's Disease
|
Phase 3 | |
Completed |
NCT01582061 -
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
|
Phase 3 | |
Recruiting |
NCT03708900 -
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease
|
Phase 2 | |
Terminated |
NCT00612066 -
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
|
Phase 2 |